EP2442649A1 - Utilisation de potentialisateurs des récepteurs métabotropiques du glutamate pour réduire la dépendance à la nicotine - Google Patents

Utilisation de potentialisateurs des récepteurs métabotropiques du glutamate pour réduire la dépendance à la nicotine

Info

Publication number
EP2442649A1
EP2442649A1 EP10790110A EP10790110A EP2442649A1 EP 2442649 A1 EP2442649 A1 EP 2442649A1 EP 10790110 A EP10790110 A EP 10790110A EP 10790110 A EP10790110 A EP 10790110A EP 2442649 A1 EP2442649 A1 EP 2442649A1
Authority
EP
European Patent Office
Prior art keywords
methyl
oxadiazol
piperazin
ylmethyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10790110A
Other languages
German (de)
English (en)
Other versions
EP2442649A4 (fr
Inventor
Joseph Frey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP2442649A1 publication Critical patent/EP2442649A1/fr
Publication of EP2442649A4 publication Critical patent/EP2442649A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Abstract

La présente invention concerne des procédés d'utilisation de potentialisateurs de récepteurs de glutamate pour réduire la consommation de nicotine, réduire l'envie de fumer ou de mâcher du tabac ou induire l'arrêt du tabagisme.
EP10790110A 2009-06-19 2010-06-16 Utilisation de potentialisateurs des récepteurs métabotropiques du glutamate pour réduire la dépendance à la nicotine Withdrawn EP2442649A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847809P 2009-06-19 2009-06-19
PCT/US2010/038802 WO2010148074A1 (fr) 2009-06-19 2010-06-16 Utilisation de potentialisateurs des récepteurs métabotropiques du glutamate pour réduire la dépendance à la nicotine

Publications (2)

Publication Number Publication Date
EP2442649A1 true EP2442649A1 (fr) 2012-04-25
EP2442649A4 EP2442649A4 (fr) 2013-04-03

Family

ID=43356736

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10790110A Withdrawn EP2442649A4 (fr) 2009-06-19 2010-06-16 Utilisation de potentialisateurs des récepteurs métabotropiques du glutamate pour réduire la dépendance à la nicotine

Country Status (4)

Country Link
EP (1) EP2442649A4 (fr)
JP (1) JP2012530710A (fr)
CN (1) CN102548407A (fr)
WO (1) WO2010148074A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102198A1 (fr) 2018-11-13 2020-05-22 Incyte Corporation Dérivés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k
WO2020102216A1 (fr) 2018-11-13 2020-05-22 Incyte Corporation Dérivés hétécycliques substitués utiles en tant qu'inhibiteurs de pi3k

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420719D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D.R. HELTON ET AL: "LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats", NEUROPHARMACOLOGY, vol. 36, no. 11-12, 1 November 1997 (1997-11-01), pages 1511-1516, XP055049732, ISSN: 0028-3908, DOI: 10.1016/S0028-3908(97)00170-6 *
IVÁN COLLADO ET AL: "(2 S ,1' S ,2' S ,3' R )-2-(2'-Carboxy-3'-methylcyclopropyl) Glycine Is a Potent and Selective Metabotropic Group 2 Receptor Agonist with Anxiolytic Properties", JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 17, 1 August 2002 (2002-08-01), pages 3619-3629, XP055049936, ISSN: 0022-2623, DOI: 10.1021/jm0110486 *
LIECHTI MATTHIAS E ET AL: "Role of the glutamatergic system in nicotine dependence dependence - Implications for the discovery and development of new pharmacological smoking cessation therapies", CNS DRUGS, vol. 22, no. 9, 2008, pages 705-724, XP002690433, ISSN: 1172-7047 *
See also references of WO2010148074A1 *

Also Published As

Publication number Publication date
WO2010148074A1 (fr) 2010-12-23
JP2012530710A (ja) 2012-12-06
CN102548407A (zh) 2012-07-04
EP2442649A4 (fr) 2013-04-03

Similar Documents

Publication Publication Date Title
Freitas et al. In vivo pharmacological interactions between a type II positive allosteric modulator of α7 nicotinic ACh receptors and nicotinic agonists in a murine tonic pain model
US20080081804A1 (en) Combination of Sabcomeline with a Neuroleptic Agent to Treat Psychotic Disorders
US20040082543A1 (en) Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
KR20100054812A (ko) 항정신병제 조합 치료제를 사용하여 정신분열증을 치료하기 위한 방법 및 조성물
EP0279114B1 (fr) Médicaments pour le traitement ou la prévention du syndrome associé à un état de manque
EP1699488A2 (fr) Combinaison therapeutique d'amelioration neuro-cognitive et de traitement de troubles psychotiques
EP3446565B1 (fr) Procédés pour le traitement de la prise de poids induite par des antipsychotiques
MX2007011436A (es) Ligando del receptor nicotinico neuronal 7 y composiciones antipsicoticas.
CA2644656A1 (fr) Traitement de la douleur
JP2002308801A (ja) うつ病、強迫疾患および精神病の組み合わせ治療
AU2011215870B2 (en) Methods and compositions for improving cognitive function
JP2014196328A (ja) ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤
MXPA02001198A (es) Tratamiento de combinacion para depresion y ansiedad.
WO2010148074A1 (fr) Utilisation de potentialisateurs des récepteurs métabotropiques du glutamate pour réduire la dépendance à la nicotine
US20090318414A1 (en) Mono and Combination Therapy with M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Prodromal Syndrome
EP0345931B1 (fr) Certains mélanges PAF antagonistes/antihistamine et procédés
US6455552B1 (en) Combination of a GABAA α5 inverse agonist and a muscarinic agonist
CA2238815A1 (fr) Composition servant a traiter la douleur
WO2010064047A1 (fr) Utilisation de sabcomeline pour le traitement de l'add ou de l'adhd
KR20030010740A (ko) 신경변성 질환의 예방 및 치료약
JP5557409B2 (ja) （ｓ）−２−（ベンジルアミノメチル）−２，３，８，９−テトラヒドロ−７ｈ−１，４−ジオキシノ（２，３）ｅインドール−８−オンと神経遮断薬との組合せ
JPH10508027A (ja) 不安を治療する方法
Slassi et al. Novel serotonergic and non-serotonergic migraine headache therapies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120104

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/445 20060101ALI20130122BHEP

Ipc: A61K 31/44 20060101ALI20130122BHEP

Ipc: A01N 43/40 20060101AFI20130122BHEP

Ipc: A61P 25/34 20060101ALN20130122BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/44 20060101ALI20130219BHEP

Ipc: A01N 43/40 20060101AFI20130219BHEP

Ipc: A61K 31/445 20060101ALI20130219BHEP

Ipc: A61P 25/34 20060101ALN20130219BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20130228

17Q First examination report despatched

Effective date: 20130418

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130829